To the Editor,

We sincerely thank the author(s) for their interest and valuable comments on our manuscript titled "Evaluation of the effect of non-ergot dopamine agonists on left ventricular systolic function with speckle tracking echocardiography" ([@ref1]).

As you mentioned, heart failure (HF) is classified according to left ventricle ejection fraction (LVEF) and includes a wide range of patients-those with preserved LVEF (≥50%), those with reduced LVEF (\<40%), and those with mildly reduced LVEF (40%--49%) ([@ref2]).

The diagnosis of HFpEF is more difficult than that of HFrEF. Patients with HFpEF generally have increased LV wall thickness and/or increased left atrial (LA) size as a sign of increased filling pressures, and most have diastolic dysfunction in echocardiographic examination.

The term HF is used to describe the symptomatic syndrome. As ESC guidelines recommend, HF diagnosis should be evaluated based on the patient's prior clinical history \[e.g., coronary artery disease ([@ref2]), arterial hypertension, diuretic use\], presenting symptoms, and physical examination. If at least one element is abnormal, then plasma natriuretic peptides should be measured. Our study patients were asymptomatic, and their physical examination results were normal; therefore, HF was not considered in our patients, and we did not measure natriuretic peptides. If we had measured these, then we may have obtained additional information.

The main aim of our study was to evaluate possible subclinical deterioration of the LV. We evaluated systolic functions with speckle-tracking echocardiography-based strain, and global longitudinal strain values were in the normal ranges in the study groups. We evaluated the diastolic functions with conventional and tissue Doppler echocardiography. An important structural parameter in diastolic function determination is LA volume index, which was in the normal range in our patients. The E/e′ value, an important functional indicator of diastolic dysfunction, were in the normal range in our patients.

Future prospective studies with larger sample sizes should be planned, and particularly adding biomarkers, such as natriuretic peptides, to the investigation may provide additional information.
